AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21150558 — intervention group
Group type: EXPERIMENTAL
Intervention: Interruption of protease inhibitor regimens
Number of subjects: 3719
Study 21150558 — intervention group
Group type: COMPARATOR
Intervention: NNRTI-based regimen
Number of subjects: 3719
Study 18429758 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (n=29)
Number of subjects: 81
Study 18429758 — intervention group
Group type: EXPERIMENTAL
Intervention: Continual treatment with Metformin for 12 months (n=30)
Number of subjects: 81
Study 18429758 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (Control group, n=12)
Number of subjects: 81
Study 18429758 — intervention group
Group type: COMPARATOR
Intervention: Patients never treated with Metformin (n=8)
Number of subjects: 81
Study 16492274 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery harvesting (study group)
Number of subjects: 20
Study 16492274 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 14640237 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (4 to 8 mg once-daily) added to ramipril (5 - 7.5 mg/day) for 16 weeks
Number of subjects: 32
Study 14640237 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to ramipril (5 - 7.5 mg/day) for 16 weeks
Number of subjects: 32
Study 10758305 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating chemoradiotherapy or partly accelerated radiotherapy
Number of subjects: 115
Study 10758305 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 115
Study 8620276 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative infusion cholangiography (PIC)
Number of subjects: 1042
Study 8620276 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative cholangiography (IOC)
Number of subjects: 1042
Study 8620276 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile duct exploration
Number of subjects: 1042
Study 8620276 — intervention group
Group type: COMPARATOR
Intervention: Cholecystectomy alone
Number of subjects: 1042
Study 8620276 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 1042
Study 1478806 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal dilatation
Number of subjects: 0
Study 1478806 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral subcutaneous sphincterotomy
Number of subjects: 0
Study 1478806 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemorrhoidectomy
Number of subjects: 0
Study 6369522 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g/day) + Intensive antacid treatment
Number of subjects: 81
Study 6369522 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (1 g/day) + Placebo treatment
Number of subjects: 81
Study 31600383 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine Tenofovir Concentrations
Number of subjects: 0
Study 29775203 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal dynamic treatment regime
Number of subjects: 0
Study 29775203 — intervention group
Group type: EXPERIMENTAL
Intervention: Support vector machines classification technique
Number of subjects: 0
Study 29775203 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation studies
Number of subjects: 0
Study 29775203 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential, multiple assignment randomized clinical trial
Number of subjects: 0
Study 27435163 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1,000 mg twice daily
Number of subjects: 500
Study 27435163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 24239662 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 19184
Study 24239662 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 19184
Study 22356669 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis-dependent patients
Number of subjects: 242
Study 22356669 — intervention group
Group type: COMPARATOR
Intervention: Cocaine-dependent patients
Number of subjects: 242
Study 21049213 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone calls
Number of subjects: 354
Study 21049213 — intervention group
Group type: COMPARATOR
Intervention: No phone calls
Number of subjects: 354
Study 18503642 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐intensive EoP intervention (counseling and supervised exercise) - 4 months of group‐based supervised training and five motivational counseling sessions.
Number of subjects: 52
Study 18503642 — intervention group
Group type: COMPARATOR
Intervention: Low‐intensive intervention (counseling) - attended four motivational counseling sessions.
Number of subjects: 52
Study 15671108 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate diet (n = 22)
Number of subjects: 41
Study 15671108 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (n = 19)
Number of subjects: 41
Study 12181246 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m²) followed by AC (60/600 mg/m²)
Number of subjects: 33
Study 12181246 — intervention group
Group type: EXPERIMENTAL
Intervention: AC (60/600 mg/m²) followed by Docetaxel (100 mg/m²)
Number of subjects: 33
Study 10359886 — intervention group
Group type: EXPERIMENTAL
Intervention: AA-2414 (80 mg/day)
Number of subjects: 31
Study 7732331 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (40 mg before breakfast)
Number of subjects: 248
Study 7732331 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (300 mg at bedtime)
Number of subjects: 248
Study 1695449 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA, Aspirin) challenge
Number of subjects: 17
Study 1695449 — intervention group
Group type: COMPARATOR
Intervention: Placebo test
Number of subjects: 17
Study 108734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous THC, 30‐‐44.8 microgram/kg
Number of subjects: 4
Study 108734 — intervention group
Group type: COMPARATOR
Intervention: Combined autonomic blockade (i.v. saline, 0.04 mg/kg atropine sulfate, 0.2 mg/kg propranolol, or both)
Number of subjects: 4
Study 31786980 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum urate level ≥6.8 mg/dL (hyperuricemia)
Number of subjects: 900
Study 31786980 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum urate level 6.0 to <6.8 mg/dL
Number of subjects: 900
Study 31786980 — intervention group
Group type: EXPERIMENTAL
Intervention: Apparent treatment-resistant hypertension (systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg on 3 antihypertensive medications or use of ≥4 antihypertensive medications)
Number of subjects: 900
Study 31786980 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of antihypertensive medication classes
Number of subjects: 900
Study 31786980 — intervention group
Group type: COMPARATOR
Intervention: Serum urate level <6.0 mg/dL (reference)
Number of subjects: 900
Study 30876658 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate
Number of subjects: 99
Study 27120192 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematic alignment with custom-made cutting guides
Number of subjects: 200
Study 27120192 — intervention group
Group type: COMPARATOR
Intervention: Mechanical alignment (control group)
Number of subjects: 200
Study 26651344 — intervention group
Group type: EXPERIMENTAL
Intervention: Care pathway based on urodynamic tests with invasive multichannel cystometry
Number of subjects: 100
Study 26651344 — intervention group
Group type: COMPARATOR
Intervention: Care pathway based on non-invasive routine tests
Number of subjects: 100
Study 26651344 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive urodynamics
Number of subjects: 100
Study 24456787 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin plus Tolterodine
Number of subjects: 104
Study 24456787 — intervention group
Group type: COMPARATOR
Intervention: Terazosin
Number of subjects: 104
Study 24456787 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine
Number of subjects: 104
Study 24456787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 20473950 — intervention group
Group type: EXPERIMENTAL
Intervention: Solar vitamin D effective UV radiation (VD dose)
Number of subjects: 41811
Study 20473950 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary vitamin D intake
Number of subjects: 41811
Study 20473950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun-seeking holidays
Number of subjects: 41811
Study 20473950 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of solarium
Number of subjects: 41811
Study 20473950 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of sunburn
Number of subjects: 41811
Study 19049753 — intervention group
Group type: EXPERIMENTAL
Intervention: ET‐AR antagonist (sitaxsentan) 1 mg/kg
Number of subjects: 44
Study 19049753 — intervention group
Group type: EXPERIMENTAL
Intervention: ET‐AR antagonist (sitaxsentan) higher doses
Number of subjects: 44
Study 19049753 — intervention group
Group type: EXPERIMENTAL
Intervention: ET‐AR antagonist (sitaxsentan)
Number of subjects: 44
Study 19049753 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control group)
Number of subjects: 44
Study 16972512 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive indoor smoking policy
Number of subjects: 14237
Study 16972512 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive outdoor smoking policy
Number of subjects: 14237
Study 16972512 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire to breathe clean air vs. desire to smoke
Number of subjects: 14237
Study 14624406 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (high-CHO: 58% of energy as CHO)
Number of subjects: 65
Study 14624406 — intervention group
Group type: EXPERIMENTAL
Intervention: High-monounsaturated fatty acid diet (high-MUFA: fat, 40% of energy and 22% as MUFA)
Number of subjects: 65
Study 14624406 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (high-CHO)
Number of subjects: 65
Study 14624406 — intervention group
Group type: EXPERIMENTAL
Intervention: High-monounsaturated fatty acid diet (high-MUFA)
Number of subjects: 65
Study 10919606 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of HHV‐7 DNA in peripheral blood leucocytes
Number of subjects: 37
Study 10919606 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV disease
Number of subjects: 37
Study 10919606 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor-recipient CMV serostatus
Number of subjects: 37
Study 1445448 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-deazaaminopterin (10-DAM)
Number of subjects: 18
Study 1445448 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 18
Study 4081994 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training
Number of subjects: 90
Study 4081994 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychological intervention)
Number of subjects: 90
Study 30979610 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperhomocysteinaemia (HHCY) group
Number of subjects: 936
Study 30979610 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome group
Number of subjects: 936
Study 29075782 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory organizational-level workplace intervention
Number of subjects: 404
Study 29075782 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 404
Study 26703220 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500mg twice daily
Number of subjects: 26
Study 26703220 — intervention group
Group type: COMPARATOR
Intervention: Ethinyl estradiol-cyproterone acetate for 21 days followed by 7 days drug-free
Number of subjects: 26
Study 24673793 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnuts (28.4 g, 6/week)
Number of subjects: 20
Study 24673793 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 FA enriched egg (6/week)
Number of subjects: 20
Study 24673793 — intervention group
Group type: COMPARATOR
Intervention: Standard egg (6/week)
Number of subjects: 20
Study 23154392 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted colon resection (LCR)
Number of subjects: 601
Study 23154392 — intervention group
Group type: COMPARATOR
Intervention: Open colon resection (OCR)
Number of subjects: 601
Study 20726911 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Retreatment files
Number of subjects: 90
Study 20726911 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtwo Retreatment files
Number of subjects: 90
Study 20726911 — intervention group
Group type: EXPERIMENTAL
Intervention: Twisted Files
Number of subjects: 90
Study 20726911 — intervention group
Group type: COMPARATOR
Intervention: Resilon/Real Seal
Number of subjects: 90
Study 20726911 — intervention group
Group type: COMPARATOR
Intervention: gutta-percha/AH plus
Number of subjects: 90
Study 18796688 — intervention group
Group type: COMPARATOR
Intervention: 1-minute balloon inflation
Number of subjects: 48
Study 18796688 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-minute balloon inflation
Number of subjects: 48
Study 15802405 — intervention group
Group type: EXPERIMENTAL
Intervention: Unopposed transdermal estradiol (14 microg per day)
Number of subjects: 417
Study 15802405 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 417
Study 12161495 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 40 mg daily with fatty liver (group C)
Number of subjects: 39
Study 12161495 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 40 mg daily without fatty liver (group B)
Number of subjects: 39
Study 12161495 — intervention group
Group type: COMPARATOR
Intervention: No tamoxifen (group A)
Number of subjects: 39
Study 10210764 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral granisetron 1 mg twice a day on day 1, followed by metoclopramide 60 mg on day 2 and 3
Number of subjects: 198
Study 10210764 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ondansetron 8 mg on day 1, followed by ondansetron 8 mg tablet twice a day on day 2 and 3
Number of subjects: 198
Study 10210764 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral granisetron followed by metoclopramide
Number of subjects: 198
Study 10210764 — intervention group
Group type: COMPARATOR
Intervention: Intravenous plus oral ondansetron
Number of subjects: 198
Study 8540613 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant combination therapy with flutamide and an LHRH agonist for 3 months
Number of subjects: 96
Study 1945205 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dihydrotestosterone
Number of subjects: 5
Study 1945205 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone (Control)
Number of subjects: 5
Study 6842586 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuffled sequence
Number of subjects: 0
Study 6842586 — intervention group
Group type: EXPERIMENTAL
Intervention: Representative sequence
Number of subjects: 0
Study 30074050 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 410
Study 30074050 — intervention group
Group type: COMPARATOR
Intervention: High-quality usual care
Number of subjects: 410
Study 30261474 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 3977
Study 30261474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3977
Study 30261474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathepsin B
Number of subjects: 3977
Study 30261474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathepsin S
Number of subjects: 3977
Study 27041692 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide plus G-CSF (Arm A)
Number of subjects: 38
Study 27041692 — intervention group
Group type: COMPARATOR
Intervention: G-CSF alone (Arm B)
Number of subjects: 38
Study 25291725 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant
Number of subjects: 0
Study 22325127 — intervention group
Group type: EXPERIMENTAL
Intervention: Suubi intervention
Number of subjects: 283
Study 19923998 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured patient group education (IBS school)
Number of subjects: 143
Study 19923998 — intervention group
Group type: COMPARATOR
Intervention: Written information (guidebook)
Number of subjects: 143
Study 17356317 — intervention group
Group type: EXPERIMENTAL
Intervention: O6MWT (walking test with supplemental oxygen)
Number of subjects: 31
Study 17356317 — intervention group
Group type: COMPARATOR
Intervention: A6MWT (walking test in room-air conditions)
Number of subjects: 31
Study 16330684 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan at a target dose of 32 mg once daily
Number of subjects: 7599
Study 16330684 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 7599
Study 12480442 — intervention group
Group type: COMPARATOR
Intervention: Pramipexole
Number of subjects: 0
Study 12480442 — intervention group
Group type: COMPARATOR
Intervention: Ropinirole
Number of subjects: 0
Study 10458211 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin at 100 mg/m2/wk concurrent with radiation therapy
Number of subjects: 283
Study 10458211 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 283
Study 7597774 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-derived vaccine (0.5 ml, 10 micrograms HBsAg)
Number of subjects: 78
Study 7597774 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-derived vaccine (0.5 ml, 25 micrograms HBsAg)
Number of subjects: 78
Study 7597774 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast-derived recombinant hepatitis B vaccine (0.5 ml, 10 micrograms HBsAg)
Number of subjects: 78
Study 7597774 — intervention group
Group type: EXPERIMENTAL
Intervention: Hevac B (0.5 ml)
Number of subjects: 78
Study 1754656 — intervention group
Group type: EXPERIMENTAL
Intervention: bright white light (2,500 lx)
Number of subjects: 42
Study 1754656 — intervention group
Group type: COMPARATOR
Intervention: dim red light (50 lx)
Number of subjects: 42
Study 6805026 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg CERM 3726
Number of subjects: 6
Study 6805026 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg CERM 3726
Number of subjects: 6
Study 6805026 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg CERM 3726
Number of subjects: 6
Study 30427054 — intervention group
Group type: EXPERIMENTAL
Intervention: Midlateral subacromial injection
Number of subjects: 50
Study 30427054 — intervention group
Group type: COMPARATOR
Intervention: Posterior subacromial injection
Number of subjects: 50
Study 30427054 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Midlateral and Posterior)
Number of subjects: 50
Study 27943533 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for anorexia nervosa (AN)
Number of subjects: 170
Study 27943533 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers of more severely ill patients
Number of subjects: 170
Study 27943533 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers of adolescent AN patients
Number of subjects: 170
Study 27943533 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 2.5 years
Number of subjects: 170
Study 24844869 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (2000 IU/d)
Number of subjects: 56
Study 25610505 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL (Bronchoalveolar Lavage)
Number of subjects: 73
Study 25610505 — intervention group
Group type: COMPARATOR
Intervention: EA (Endotracheal Aspiration)
Number of subjects: 73
Study 25610505 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL
Number of subjects: 73
Study 25610505 — intervention group
Group type: COMPARATOR
Intervention: EA
Number of subjects: 73
Study 22738209 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-ml sports drink with 1 g of GABA (trial G)
Number of subjects: 8
Study 22738209 — intervention group
Group type: COMPARATOR
Intervention: 200-ml sports drink without GABA (trial C)
Number of subjects: 8
Study 20035589 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) treatment for 6 months
Number of subjects: 21
Study 20035589 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 21
Study 17339106 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Care (IC)
Number of subjects: 113
Study 17339106 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 113
Study 15155119 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0
Study 15155119 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride + Doxazosin
Number of subjects: 0
Study 15155119 — intervention group
Group type: COMPARATOR
Intervention: Finasteride alone
Number of subjects: 0
Study 15155119 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin
Number of subjects: 0
Study 12171979 — intervention group
Group type: EXPERIMENTAL
Intervention: urokinase + abciximab
Number of subjects: 26
Study 12171979 — intervention group
Group type: COMPARATOR
Intervention: urokinase
Number of subjects: 26
Study 9722799 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FP ANS) 200 microgram once daily
Number of subjects: 600
Study 9722799 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg once daily
Number of subjects: 600
Study 9722799 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FP ANS) plus loratadine
Number of subjects: 600
Study 9722799 — intervention group
Group type: COMPARATOR
Intervention: Placebo (aqueous nasal spray plus tablet)
Number of subjects: 600
Study 9722799 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FP ANS)
Number of subjects: 600
Study 7806687 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 381
Study 7806687 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 381
Study 2527121 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (oral, 1 g once daily)
Number of subjects: 16
Study 2527121 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (intravenous, 500 mg in 100 ml of physiological saline)
Number of subjects: 16
Study 2527121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 415478 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, vincristine, prednisone, and doxorubicine or VM 26 (induction chemotherapy course for 15-20 days)
Number of subjects: 66
Study 415478 — intervention group
Group type: COMPARATOR
Intervention: Previous treatment with cyclophosphamide, vincristine, and prednisone only
Number of subjects: 66